Skip to main content

Advances in Retinal Imaging and Applications in Diabetic Retinopathy Screening: A Review


Rising prevalence of diabetes worldwide has necessitated the implementation of population-based diabetic retinopathy (DR) screening programs that can perform retinal imaging and interpretation for extremely large patient cohorts in a rapid and sensitive manner while minimizing inappropriate referrals to retina specialists. While most current screening programs employ mydriatic or nonmydriatic color fundus photography and trained image graders to identify referable DR, new imaging modalities offer significant improvements in diagnostic accuracy, throughput, and affordability. Smartphone-based fundus photography, macular optical coherence tomography, ultrawide-field imaging, and artificial intelligence-based image reading address limitations of current approaches and will likely become necessary as DR becomes more prevalent. Here we review current trends in imaging for DR screening and emerging technologies that show potential for improving upon current screening approaches.

Diabetic Retinopathy Screening Programs in Modern Ophthalmic Practice

Over the past few decades, the global prevalence of diabetes in adults has nearly doubled, increasing from 4.7% in 1980 to 8.5% in 2014, with rapid increases in middle- and low-income countries [1]. The World Health Organization projects that diabetes will be the seventh leading cause of death worldwide by 2030 [1]. Among diabetic complications, the prevalence of diabetic retinopathy (DR), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) among individuals with diabetes is approximately 35%, 7%, and 3–7%, respectively [2,3,4].

Diabetic eye disease is a prime candidate for a universal screening program. It is one of the most common causes of legal blindness in developed countries, with DME and PDR being the two major vision-threatening complications of diabetes [5, 6]. Treatment before the onset of advanced DR is highly effective in preventing visual loss [7, 8]. However, patients often remain asymptomatic and do not present until advanced complications such as vitreous hemorrhage or retinal detachment develop, by which time treatment outcomes are less favorable and often incur high costs [9, 10]. A universal screening program for DR aims to identify high-risk individuals and instigate treatment before complications develop [11, 12].

The first diabetic retinopathy screening programs were implemented during the 1980s and early 1990s [13,14,15]. These early programs were tremendously successful in reducing the incidence of DR-related blindness. In Stockholm early DR screening efforts decreased specialist referrals for DR-related blindness by an average of 47% per year over a 5-year period following the introduction of DR screening in 1991 [14]. Implementation of DR screening in the UK had similarly impressive results, with a 49% reduction in DR-related blindness in Wales during the 2007–2015 period that was attributed to DR screening programs [16].

Retinal Photography for Diabetic Retinopathy Screening

Currently, the International Council of Ophthalmology (ICO) guidelines for DR screening include retinal examination with either (1) direct or indirect ophthalmoscopy or slit-lamp biomicroscopy or (2) mydriatic or nonmydriatic fundus imaging with ≥ 30° mono- or stereophotography, with or without OCT. Retinal imaging review should be by an examiner sufficiently well trained to assess DR severity [17]. The level of DR classification afforded by screening programs is stipulated by the American Teleophthalmology Associations (ATA; Table 1), with category 1 providing a level of detail useful for population screening.

Table 1 Validation levels of diabetic retinopathy used by the ATA.

Fundus photography for DR screening has become widely adopted worldwide as the availability of imaging platforms increases [18, 19]. Although binocular slit-lamp ophthalmoscopy has remained a standard against which other DR screening approaches are judged, fundus photography is more cost-effective and does not require ophthalmologist consultation [20,21,22,23]. With training and adequate retinal image quality, graders can differentiate eyes with different severities of DR and identify eyes with PDR that require urgent referral for treatment. Meta-analysis of 20 studies with 1,960 participants yielded a combined sensitivity for DR screening programs of 80% in detecting no DR or PDR, more than 70% for detecting mild or moderate nonproliferate diabetic retinopathy (NPDR) and clinically significant macular edema (CSME), and 53% in detecting severe NPDR [24]. The specificity of screening programs was typically > 90% in the same study.

Improvements in fundus photography, particularly since the 1970s, have resulted in increased photographic quality and throughput that has facilitated implementation of teleophthalmology programs. Digital cameras are now approaching the potential resolution of film cameras, and digital photography is considered a reliable alternative to traditional film-based seven-field photography used in the Early Treatment of Diabetic Retinopathy Study (ETDRS) [25, 26]. Current fundus cameras have resolutions in the 20 megapixel range (e.g., Canon CR-2), which exceeds the 2–3 megapixel resolution required to display a single microaneurysm at the minimum identifiable diameter of 2–3 pixels [27]. Incorporation of image sensors in the range of 64 megapixels, however, is required to achieve sharp focus everywhere for 45° field diameter images using standard flash photography red-green-blue (RGB) image sensors [28, 29]. At present, such cameras remain prohibitively expensive for many government screening programs.

Mydriatic and Nonmydriatic Fundus Photography

In terms of pupil dilation, there is no international consensus on the optimal approach to DR screening. Comparative trials of mydriatic and nonmydriatic fundus photography have demonstrated that mydriasis significantly reduces the proportion of ungradable photographs, from 19–26% to 4–5%, and improves both the sensitivity (77–86% vs. 81–94%) and specificity (77–95% vs. 86–98%) of DR detection compared with undilated photography [24, 30,31,32]. Despite this, for patient convenience and logistical reasons, many programs employ nonmydriatic photography, with mydriasis being reserved for cases where ungradable images are obtained (Table 2).

Table 2 Diabetic retinopathy screening programs for different ATA diabetic retinopathy characterization levels.

Single and Multiple Field Fundus Photography

Diabetic retinopathy severity grading, as established by the ETDRS with the modified Airlie House classification, requires a laborious process of capturing stereoscopic photos of seven standardized 30° fundus fields encompassing a horizontal fundus viewing angle of 75°. Photos are then mounted in plastic sheets and viewed against light boards using stereo viewers at 5× magnification [33]. While this approach remains the gold standard for photographic diagnosis and grading of DR, it is clearly inappropriate for large-scale population screening [34]. Dilated single-field 45° fundus photography has a sensitivity of 76–84% and specificity of 82–92% for DR [32]. In the UK, nonmydriatic fundus cameras are used for mydriatic photography with two 45° fields (one fovea centered and one disc centered) [35]. Most other programs employ single 45° field fundus photos or two- and three-field photography for screening purposes (Table 2).

Optical Coherence Tomography for Diabetic Macular Edema Screening

Although many current screening programs are efficient in detecting referable DR, the accurate diagnosis of DME is more challenging. An especially problematic aspect of two-dimensional fundus photography for DME detection is the inability to reliably identify retinal thickening. The English National Screening Program (ENSP) for DR employs three photographic markers, namely (1) exudates within one disc diameter of the fovea, (2) circinates within the macula, and (3) microaneurysms or hemorrhages within one disc diameter of the fovea associated with best corrected visual acuity of worse than 6/12, as surrogates for DME [35]. This approach, while reasonable within the limits of currently used imaging platforms, has limited diagnostic accuracy. Only 17% of patients with hemorrhages or microaneurysms within one disc diameter of the fovea and reduced visual acuity had thickening on macular OCT, while only 6% had macular edema. Similarly, only 27% of those with macular exudates within one disc diameter of the fovea or circinates within two disc diameters of the fovea had thickening on macular OCT [36]. A cross-sectional observational study from Hong Kong recorded a false-positive rate of 86.6% for macular edema using conventional fundus photography screening methods [37]. Among eyes proven to have macular edema on OCT, approximately one quarter to one-third are missed by fundus photography screening [38].

Several studies have investigated the incorporation of macular OCT as part of a DR screening program to determine if this approach is beneficial from a medical and cost-effectiveness perspective. Prescott et al. found that use of OCT in cases where color fundus photos suggested the presence of macular edema resulted in direct cost savings of 16–17% because of fewer unnecessary referrals without a measurable decrease in medical benefits [19]. A cost-effectiveness study of DME screening in Hong Kong found that although the screening cost per patient increased by 35% if OCT was performed on all patients undergoing color fundus photography, the cost per quality-adjusted life-year was reduced by 45% (RW, unpublished). In contrast to these promising studies, more recent work from Australia that compared DR screening using a standard color fundus photography (CentreVue DRS fundus camera, Padova) with a combined fundus camera and OCT instrument (3D OCT-1 Maestro, Topcon, Tokyo) concluded that there was no added benefit of OCT [39]. This was due to the substantial increase in ungradable fundus photos obtained with the combined fundus camera/OCT scanner that required specialist referral, negating the benefit of reduced referrals for macular edema based on OCT imaging. This negative result, however, was largely specific to the scanning instrument chosen and would likely have been overcome with the use of a dedicated fundus camera and OCT scanner setup. That said, significant challenges remain to the addition of dedicated macular OCT scans to current DR screening protocols, such as the relatively low availability of OCT machines and expertise of operators in general outpatient clinics for screening due to cost constraints.

Grading Fundus Photos for Signs of Diabetic Retinopathy

Telemedicine Standards for DR Screening

The degree to which DR severity and thus referral and treatment urgency is assessed varies has been categorized into four levels by the ATA. Category 1 includes programs that can distinguish no or minimal DR from more than minimal DR, while category 4 enables complete categorization of DR into mild, moderate, and severe nonproliferative disease, early and high-risk proliferative disease, and whether macular edema is present (Table 2). Current DR screening programs employ ATA categories 1–3 (Table 2); as a result, the incidence of DR and DR-related blindness have fallen dramatically [35]. In tandem, the implementation of telemedicine DR screening programs is cost-effective compared with physician-based DR screening approaches and generates similar health outcomes [40].

Automated DR Image Assessment Systems

A relative scarcity of ophthalmologists necessitates the use of specially trained non-ophthalmologist and non-physician graders for DR screening. Such graders are used in most developed countries nowadays (Table 2), and previous work has demonstrated that this approach is adequate for DR detection [41,42,43,44]. Despite this, the growing prevalence of diabetes has placed greater pressure on healthcare systems to increase screening throughput while minimizing costs. Automated grading for diabetic retinopathy was reported in the 1990s, when Gardner and colleagues described the use of an artificial neural network capable of detecting diabetic retinopathy with 88% sensitivity and 83% specificity relative to an ophthalmologist [45]. Their system and others like it employed pattern recognition algorithms trained to identify specific retinopathy features, such as microaneurysms, and as such required time-consuming pre-processing of training images to isolate clinically important features and develop mathematical descriptors of different lesion types.

Deep Learning (DL) is a new iteration of artificial intelligence (AI) that employs convolutional neural networks (CNNs) to interpret images by repititive analysis and comparison of the output with a standard (i.e., a human grader) and self-correcting if an error is made. DL is made possible by recent advances in software programming, the availability of large data sets used to train image recognition software, and high-resolution digital imaging systems [46,47,48,49,50]. Multiple studies have shown successful results in developing DL algorithms that are capable of identifying referable DR without the prior need to teach the computer systems specific features of DR. The sensitivities and specificities of these approaches are in general > 90% and 95%, respectively [44, 47,48,49]. Importantly, the negative predictive value of current DL algorithms for DR detection is now upwards of 99%, with less than 1% probability of missing severe NPDR, PDR, or macular edema [51]. Current generation DL algorithms that employ standard color fundus photos have already achieved grading performance similar to retinal specialists [52, 53]. A large-scale trial of a DL algorithm trained for DR screening with a multi-ethnic data set also included additional algorithms for detection of glaucoma and age-related macular generation (AMD) [48]. Detection of possible glaucoma had a sensitivity of 96.4% (95% CI 81.7–99.9%) and specificity was 87.2% (95% CI 86.8–87.5%), while detection of possible AMD achieved a sensitivity of 93.2% (95% CI 91.1–99.8%) and specificity of 88.7% (95% CI 88.3–89.0%). More recently, DL approaches were even used for automated interpretation of macular OCT scans and demonstrated diagnostic accuracy exceeding that of trained ophthalmologists for a variety of macular diseases including DME [54].

Several DL algorithms for DR screening, including the recently FDA-approved IDx-DR algorithm [51, 55], have been reported. These can broadly be grouped into lesion-based disease detection systems and image-based (“black box”) detection systems. Lesion-based systems are trained using known disease features of DR such as microaneurysms, blot hemorrhages, and exudates. In contrast, black box disease detection systems, such as the Google Brain system [47], are trained using fundus photographs that have been graded for DR, but the specific pathologic features being detected by the algorithm remain unknown, and output is given simply as a positive or negative response to a disease state.

Clearly DL approaches hold great promise for rapid, reliable, and cost-effective screening for diabetic retinopathy. However, several important challenges remain that complicate the introduction of these algorithms into large-scale screening programs. Despite the impressive performance previously reported by the Google Brain team using an image-based DR detection system, recently presented work from Lynch et al. [56] revealed that this “black box” approach to DR screening is highly vulnerable to seemingly innocuous alterations of fundus images. Using a series of reference DR fundus photos containing typical features of DR, slight pixel modifications (0.12–0.51% of total pixels) were introduced into the images that were essentially imperceptible to human readers and did not obviously alter the appearance of the DR lesions. These altered photos were then presented to an image-based CNN previously trained with half a million DR photos. The modified images were classified as normal by the image-based CNN, while the lesion-based system still detected DR. In light of this work, the potential value of image-based CNNs in identifying novel fundus signs of DR needs to be balanced against their potential failure to detect clinically obvious disease.

Another limitation of many current DL approaches is the binary nature of algorithm development. Most contemporary CNNs are trained using normal fundus images and images with a single disease, such as DR. The variety of retinal pathologies and differences in referral urgency make this approach inappropriate in a typical heterogenous population that would attend retinal screening programs. A recent attempt to use contemporary CNNs trained with a variety of retinal pathologies, including DR, AMD, vein and artery occlusions, hypertensive retinopathy, Coats disease, and retinitis, found that diagnostic accuracy for any particular pathology dropped precipitously with each additional disease added to the diagnostic algorithm, to as low as 20–30% after the addition of ten distinct retinal pathologies [57]. It remains to be seen whether these limitations will be overcome with the development of more sophisticated DL algorithms and more powerful computer hardware. Additionally, the usefulness of algorithms trained using retinal images from a particular population may not extend to other populations [48]. While the clinical findings of DR are largely similar between races, it is possible that DL algorithms are also recognizing new DR markers that are not shared among different populations.

Emerging Image Modalities for DR Screening

Ultrawide-Field Imaging for Diabetic Retinopathy Screening

The narrow field of view in ordinary fundus photographs (e.g., single-field 45° or even a 7-field standard ETDRS) may exclude peripheral DR lesions. This is significant when predominantly peripheral lesions (PPLs) are associated with retinal ischemia, DR progression, and development of proliferative retinopathy [58, 59]. Eyes with PPLs were shown to have a 3.2-fold increased risk of two-step or more DR progression and a 4.7-fold increased risk for progression to proliferative disease [58]. Ultrawide-field (UWF) imaging, which can image 80% of the retinal surface, is therefore a potentially important imaging modality for DR screening. Use of UWF imaging for DR screening can achieve a sensitivity up to 99% and specificity up to 97% for DR [34]. The Optos (Daytona, Optos) and Clarus 500 (Carl Zeiss, Oberkochen) are currently available UWF imaging platforms that both enable 200° field retinal imaging in only one or two images.

Optos is a scanning laser ophthalmoscope that produces retinal images of up to 200° in non-mydriatic eyes [60, 61], representing more than three times the retinal surface of traditional ETDRS seven-field photos [62]. Such images enable identification of peripheral retinal lesions of diabetic retinopathy that cannot be seen on conventional fundus photos [60] (Fig. 1). The recently released Clarus 500 captures 133° fundus photos or 200° composited photos but, unlike Optos, is able to produce true-color images that may potentially enable more accurate identification of DR lesions, although this has yet to be demonstrated in clinical trials.

Fig. 1

Comparison of standard 45° fundus photography and ultrawide-field imaging of diabetic retinopathy using the Optos imaging platform (Optos, Daytona, IL). a Diabetic retinopathy with macular edema, imaged using a 45° field fundus camera; b the same eye following panretinal photocoagulation, imaged with the Optos ultrawidefield imaging platform

The rate of ungradable fundus photos, a common cause of specialist referral in DR screening programs, was dramatically reduced when nonmydriatic UWF was employed compared with conventional nonmydriatic multifield color fundus photography in a US-based DR teleophthalmology program involving over 25,000 patients [63]. An ungradable rate per patient for DR was 2.8% with Optos UWF compared with 26.9% with multifield photography, while the ungradable rate for DME was 3.8% with Optos UWF compared with 26.2% with multifield photography. Overall, the study demonstrated an 81% reduction in ungradable fundus photos and almost twofold increased DR detection.

At present, the major constraint to widespread adoption of UWF systems such as the Optos and Clarus for DR screening programs is largely financial—such instruments cost an order of magnitude more than conventional fundus camera setups. Despite the impressive outcomes of clinical trials, it remains unclear whether the cost savings of reduced inappropriate referrals are sufficient to justify the financial outlay [64].

OCT Angiography as a Screening Tool

OCT angiography (OCT-A) is a novel noninvasive imaging modality that can detect blood flow within the retina (Fig. 2). In diabetic retinopathy, microaneurysms and retinal neovascularization can be detected using OCT-A noninvasively [65]. Although the clinical utility of OCT-A remains to be established [66], several recent works have highlighted its potential for incorporation into DR screening approaches. Accurate noninvasive grading of DR severity by OCT-A analysis has been demonstrated via analyses of foveal avascular zone acircularity [67] and retinal plexus densitometry [68,69,70]. Automation of OCT-A image analysis has also been used for quantitative assessment of DR vascular changes that correlate with visual acuity and may be useful for monitoring DR progression [71].

Fig. 2

Wide-field OCT angiograms of diabetic retinopathy using image montaging captured using the Plex Elite 9000 swept-source OCT angiography platform (Carl Zeiss AG, Oberkochen, Germany). Retinal swept-source OCT-A slabs demonstrate mild non-proliferative diabetic retinopathy with intact retinal vasculature (a) and moderate non-proliferative diabetic retinopathy and multiple foci of capillary fallout seen in the temporal macula and beyond the vascular arcades (b)

Portable Fundus Photography for Detection of Diabetic Retinopathy

Modern digital color fundus cameras, although widely available in developed regions, still typically cost many thousands of dollars, are large and cumbersome, and require specially trained ophthalmic photographers. This often limits their deployment in developing regions and in areas with underserved patient populations who are less likely to attend regular ophthalmic screening. In recent years, several manufacturers have attempted to address this problem by developing fundus photography attachments for smartphones with digital cameras. Modern smartphone cameras are capable of producing very high-quality digital images the match or exceed the resolution of dedicated clinical-grade retinal cameras, albeit with smaller image sensors. Contemporary smart phones feature ≥ 10 megapixel wide-angle and telephoto cameras with optical image stabilization and are a potentially useful alternative to conventional fundus cameras.

Fundus photography using a smartphone and handheld 20-diopter condensing lens has been successfully used to capture fundus photos [72], and since then several commercial developers have released hardware attachments and software to enable convenient fundus photography. Current smartphone-based imaging solutions are based on the incorporation of additional lens elements in line with the smartphone camera and typically come with custom software that enables capture, labeling, and secure transmission of fundus photos. Outcomes of recent prospective clinical trials with smartphone-based fundus photography systems used for DR screening are summarized in Table 3. In most reports the sensitivity for DR using images captured from smartphones is comparable to slit-lamp biomicroscopy or dedicated fundus camera imaging with the benefit of far greater affordability.

Table 3 Outcomes of clinical studies using portable retinal cameras for diabetic retinopathy screening

Given the obvious benefits of low cost and portability, there is clearly excellent potential in smartphone-based DR screening, though the questionable ability of these imaging systems to provide fundus images through undilated pupils poses a problem for screening programs that do not employ routine dilation. Concerns about acute angle closure precipitated by dilation, particularly in East Asian populations [73], may render this approach undesirable in certain regions. Portable nonmydriatic fundus cameras are widely available and have been successfully tested for DR screening (Table 3), with diagnostic performance comparable to smartphone-based systems. These devices offer somewhat better diagnostic performance than fixed fundus cameras in terms of image gradeability and diagnostic accuracy, but the benefit of portability cannot be overstated [74,75,76,77]. Several large trials have demonstrated the potential of these devices for detecting referable DR in developing regions [78,79,80,81]. It is likely that the incorporation of both smartphone-based and dedicated portable fundus cameras into DR screening programs will increase dramatically in the coming years, particular in developing countries with large rural areas where clinic review in often not feasible. Recent incorporation of AI-based automatic image grading to smartphone fundus images [82] offers potential for even further improvements to the cost-effectiveness and convenience of screening programs.


Over the past few decades, diabetic retinopathy screening programs have been implemented in essentially all developed nations and many developing nations [10, 83]. While most current screening programs employ conventional fundus photography with trained grading staff, research over the past few years has demonstrated a role for newer imaging modalities and image analysis software that has the potential to improve screening accuracy and reduce the financial burden of these increasingly expensive programs. With the dramatic increase in diabetes prevalence currently occurring worldwide, it is clear that more efficient screening programs will be required not only to ensure early detection of disease, but also to reduce inappropriate referrals to ophthalmologists for non-sight-threatening disease that is more appropriately managed with continued observation in a primary healthcare setting.

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.

    Cho NH, et al. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.

    Google Scholar 

  2. 2.

    Yau JW, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64.

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    Varma R, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–40.

    PubMed  PubMed Central  Google Scholar 

  4. 4.

    Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.

    Google Scholar 

  5. 5.

    Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.

    PubMed  Google Scholar 

  6. 6.

    Aiello LP, et al. Diabetic retinopathy. Diabetes Care. 1998;21(1):143–56.

    CAS  PubMed  Google Scholar 

  7. 7.

    Group TDRSR. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88(7):583–600.

    Google Scholar 

  8. 8.

    Group TDRSR. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 Suppl):766–85.

    Google Scholar 

  9. 9.

    Ross EL, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol. 2016;134(8):888–96.

    PubMed  Google Scholar 

  10. 10.

    Gangwani RA, et al. Diabetic retinopathy screening: global and local perspective. Hong Kong Med J. 2016;22(5):486–95.

    CAS  PubMed  Google Scholar 

  11. 11.

    Stefansson E, et al. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand. 2000;78(4):374–85.

    CAS  PubMed  Google Scholar 

  12. 12.

    Tung TH, et al. Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in Kinmen, Taiwan. J Epidemiol. 2008;18(5):225–33.

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Lau HC, et al. Mass screening for diabetic retinopathy—a report on diabetic retinal screening in primary care clinics in Singapore. Singap Med J. 1995;36(5):510–3.

    CAS  Google Scholar 

  14. 14.

    Backlund LB, Algvere PV, Rosenqvist U. New blindness in diabetes reduced by more than one-third in Stockholm County. Diabet Med. 1997;14(9):732–40.

    CAS  PubMed  Google Scholar 

  15. 15.

    Newcomb PA, Klein R. Factors associated with compliance following diabetic eye screening. J Diabet Complicat. 1990;4(1):8–14.

    CAS  Google Scholar 

  16. 16.

    Thomas RL, et al. Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007–2015. BMJ Open. 2017;7(7):e015024.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Wong TY, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125(10):1608–22.

    PubMed  Google Scholar 

  18. 18.

    Lian JX, et al. Systematic screening for diabetic retinopathy (DR) in Hong Kong: prevalence of DR and visual impairment among diabetic population. Br J Ophthalmol. 2016;100(2):151–5.

    PubMed  Google Scholar 

  19. 19.

    Prescott G, et al. Improving the cost-effectiveness of photographic screening for diabetic macular oedema: a prospective, multi-centre, UK study. Br J Ophthalmol. 2014;98(8):1042–9.

    PubMed  Google Scholar 

  20. 20.

    Scotland GS, et al. Cost-effectiveness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland. Br J Ophthalmol. 2007;91(11):1518–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Kawasaki R, et al. Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study. Ophthalmic Epidemiol. 2015;22(1):4–12.

    PubMed  Google Scholar 

  22. 22.

    Rachapelle S, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology. 2013;120(3):566–73.

    PubMed  Google Scholar 

  23. 23.

    Lin DY, et al. The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol. 2002;134(2):204–13.

    PubMed  Google Scholar 

  24. 24.

    Shi L, et al. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br J Ophthalmol. 2015;99(6):823–31.

    PubMed  PubMed Central  Google Scholar 

  25. 25.

    Bernardes R, Serranho P, Lobo C. Digital ocular fundus imaging: a review. Ophthalmologica. 2011;226(4):161–81.

    PubMed  Google Scholar 

  26. 26.

    Li HK, et al. Digital versus film Fundus photography for research grading of diabetic retinopathy severity. Investig Ophthalmol Vis Sci. 2010;51(11):5846–52.

    Google Scholar 

  27. 27.

    Taylor DJ, et al. Image-quality standardization for diabetic retinopathy screening. Expert Rev Ophthalmol. 2009;4(5):469–76.

    Google Scholar 

  28. 28.

    Cornsweet T. Pixels in fundus cameras: how many do you need? Int Agency Prev Blindness. 2015(April 3):1–5.

  29. 29.

    Tyler ME, et al. Characteristics of digital fundus camera system affecting tonal resolution in color retinal images. J Ophthalmic Photo. 2009;31:9–14.

    Google Scholar 

  30. 30.

    Scanlon PH, et al. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. Br J Ophthalmol. 2003;87(10):1258–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Scanlon PH, et al. The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. Diabet Med. 2003;20(6):467–74.

    CAS  PubMed  Google Scholar 

  32. 32.

    Murgatroyd H, et al. Effect of mydriasis and different field strategies on digital image screening of diabetic eye disease. Br J Ophthalmol. 2004;88(7):920–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Group ETDRSR. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 Suppl):786–806.

    Google Scholar 

  34. 34.

    Zimmer-Galler IE, Zeimer R. Telemedicine in diabetic retinopathy screening. Int Ophthalmol Clin. 2009;49(2):75–86.

    PubMed  Google Scholar 

  35. 35.

    Scanlon PH. The English National Screening Programme for diabetic retinopathy 2003–2016. Acta Diabetol. 2017;54(6):515–25.

    PubMed  PubMed Central  Google Scholar 

  36. 36.

    Wharton H, Gibson J, Dodson P. How accurate are photographic surrogate markers used to detect macular oedema in the English National Screening Programme? In: Royal College of Ophthalmologists Annual Congress. Birmingham: Royal College of Ophthalmologists; 2011. p. 105.

  37. 37.

    Wong RL, et al. Are we making good use of our public resources? The false-positive rate of screening by fundus photography for diabetic macular oedema. Hong Kong Med J. 2017;23(4):356–64.

    PubMed  Google Scholar 

  38. 38.

    Wang YT, et al. Comparison of prevalence of diabetic macular edema based on monocular fundus photography vs optical coherence tomography. JAMA Ophthalmol. 2016;134(2):222–8.

    PubMed  Google Scholar 

  39. 39.

    O’Halloran RA, Turner AW. Evaluating the impact of optical coherence tomography in diabetic retinopathy screening for an aboriginal population. Clin Exp Ophthalmol. 2018;46(2):116–21.

    PubMed  Google Scholar 

  40. 40.

    Nguyen HV, et al. Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore. Ophthalmology. 2016;123(12):2571–80.

    PubMed  Google Scholar 

  41. 41.

    Bhargava M, et al. Accuracy of diabetic retinopathy screening by trained non-physician graders using non-mydriatic fundus camera. Singap Med J. 2012;53(11):715–9.

    Google Scholar 

  42. 42.

    McKenna M, et al. Accuracy of trained rural ophthalmologists versus non-medical image graders in the diagnosis of diabetic retinopathy in rural China. Br J Ophthalmol. 2018;102:1471–6.

    PubMed  Google Scholar 

  43. 43.

    Deb N, et al. Screening for diabetic retinopathy in France. Diabetes Metab. 2004;30(2):140–5.

    CAS  PubMed  Google Scholar 

  44. 44.

    Owens DR, et al. Screening for diabetic retinopathy. Diabet Med. 1991;8:S4–10.

    PubMed  Google Scholar 

  45. 45.

    Gardner GG, et al. Automatic detection of diabetic retinopathy using an artificial neural network: a screening tool. Br J Ophthalmol. 1996;80(11):940–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Esteva A, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Gulshan V, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016;316(22):2402–10.

    PubMed  Google Scholar 

  48. 48.

    Ting DSW, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA. 2017;318(22):2211–23.

    PubMed  PubMed Central  Google Scholar 

  49. 49.

    Gargeya R, Leng T. Automated identification of diabetic retinopathy using deep learning. Ophthalmology. 2017;124(7):962–9.

    PubMed  Google Scholar 

  50. 50.

    Li Z, et al. Efficacy of a deep learning system for detecting glaucomatous optic neuropathy based on color fundus photographs. Ophthalmology. 2018;125(8):1199–1206.

    PubMed  Google Scholar 

  51. 51.

    Abramoff MD, et al. Improved automated detection of diabetic retinopathy on a publicly available dataset through integration of deep learning. Investig Ophthalmol Vis Sci. 2016;57(13):5200–6.

    Google Scholar 

  52. 52.

    Krause J, et al. Grader variability and the importance of reference standards for evaluating machine learning models for diabetic retinopathy. Ophthalmology. 2018;125(8):1264–72.

    PubMed  Google Scholar 

  53. 53.

    Saha SK, et al. Automated quality assessment of colour fundus images for diabetic retinopathy screening in telemedicine. J Digit Imaging. 2018.

    Article  PubMed  Google Scholar 

  54. 54.

    De Fauw J, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018;24:1342–50.

    PubMed  Google Scholar 

  55. 55.

    van der Heijden AA, et al. Validation of automated screening for referable diabetic retinopathy with the IDx-DR device in the Hoorn Diabetes Care System. Acta Ophthalmol. 2018;96(1):63–8.

    PubMed  Google Scholar 

  56. 56.

    Lynch SK, et al. Catastrophic failure in image-based convolutional neural network algorithms for detecting diabetic retinopathy. Investig Ophthalmol Vis Sci. 2017;58:3776.

    Google Scholar 

  57. 57.

    Choi JY, et al. Multi-categorical deep learning neural network to classify retinal images: a pilot study employing small database. PLoS One. 2017;12(11):e0187336.

    PubMed  PubMed Central  Google Scholar 

  58. 58.

    Silva PS, et al. Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years. Ophthalmology. 2015;122(5):949–56.

    PubMed  Google Scholar 

  59. 59.

    Silva PS, et al. Diabetic retinopathy severity and peripheral lesions are associated with nonperfusion on ultrawide field angiography. Ophthalmology. 2015;122(12):2465–72.

    PubMed  Google Scholar 

  60. 60.

    Silva PS, et al. Nonmydriatic ultrawide field retinal imaging compared with dilated standard 7-field 35-mm photography and retinal specialist examination for evaluation of diabetic retinopathy. Am J Ophthalmol. 2012;154(3):549–59.

    PubMed  Google Scholar 

  61. 61.

    Wessel MM, et al. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina. 2012;32(4):785–91.

    PubMed  Google Scholar 

  62. 62.

    Silva PS, et al. Hemorrhage and/or microaneurysm severity and count in ultrawide field images and early treatment diabetic retinopathy study photography. Ophthalmology. 2017;124(7):970–6.

    PubMed  Google Scholar 

  63. 63.

    Silva PS, et al. Identification of diabetic retinopathy and ungradable image rate with ultrawide field imaging in a National Teleophthalmology Program. Ophthalmology. 2016;123(6):1360–7.

    PubMed  Google Scholar 

  64. 64.

    Hackenthal V. New scan for diabetic eye disease is better, but at a cost. In: Medscape ophthalmology. National Libraries of Medicine. 2016.

  65. 65.

    Tan ACS, et al. An overview of the clinical applications of optical coherence tomography angiography. Eye (Lond). 2018;32(2):262–86.

    CAS  Google Scholar 

  66. 66.

    Spaide RF, et al. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1–55.

    PubMed  Google Scholar 

  67. 67.

    Krawitz BD, et al. Acircularity index and axis ratio of the foveal avascular zone in diabetic eyes and healthy controls measured by optical coherence tomography angiography. Vis Res. 2017;139:177–86.

    PubMed  Google Scholar 

  68. 68.

    Agemy SA, et al. Retinal vascular perfusion density mapping using optical coherence tomography angiography in normals and diabetic retinopathy patients. Retina. 2015;35(11):2353–63.

    PubMed  Google Scholar 

  69. 69.

    Dupas B, et al. Association between vessel density and visual acuity in patients with diabetic retinopathy and poorly controlled type 1 diabetes. JAMA Ophthalmol. 2018;136(7):721–8.

    PubMed  PubMed Central  Google Scholar 

  70. 70.

    Ting DSW, et al. Optical coherence tomographic angiography in type 2 diabetes and diabetic retinopathy. JAMA Ophthalmol. 2017;135(4):306–12.

    PubMed  Google Scholar 

  71. 71.

    Samara WA, et al. Quantification of diabetic macular ischemia using optical coherence tomography angiography and its relationship with visual acuity. Ophthalmology. 2017;124(2):235–44.

    PubMed  Google Scholar 

  72. 72.

    Lord RK, et al. Novel uses of smartphones in ophthalmology. Ophthalmology. 2010;117(6):1274e3.

    Google Scholar 

  73. 73.

    Tan GS, et al. Is routine pupil dilation safe among asian patients with diabetes? Investig Ophthalmol Vis Sci. 2009;50(9):4110–3.

    Google Scholar 

  74. 74.

    Toy BC, et al. Smartphone-based dilated fundus photography and near visual acuity testing as inexpensive screening tools to detect referral warranted diabetic eye disease. Retina. 2016;36(5):1000–8.

    PubMed  Google Scholar 

  75. 75.

    Ryan ME, et al. Comparison among methods of retinopathy assessment (CAMRA) study: smartphone, nonmydriatic, and mydriatic photography. Ophthalmology. 2015;122(10):2038–43.

    PubMed  PubMed Central  Google Scholar 

  76. 76.

    Russo A, et al. Comparison of smartphone ophthalmoscopy with slit-lamp biomicroscopy for grading diabetic retinopathy. Am J Ophthalmol. 2015;159(2):360–4.

    PubMed  Google Scholar 

  77. 77.

    Rajalakshmi R, et al. Validation of smartphone based retinal photography for diabetic retinopathy screening. PLoS One. 2015;10(9):e0138285.

    PubMed  PubMed Central  Google Scholar 

  78. 78.

    Wadhwani M, et al. Diabetic retinopathy screening programme utilising non-mydriatic fundus imaging in slum populations of New Delhi, India. Trop Med Int Health. 2018;23(4):405–14.

    PubMed  Google Scholar 

  79. 79.

    Sengupta S, et al. Screening for vision-threatening diabetic retinopathy in South India: comparing portable non-mydriatic and standard fundus cameras and clinical exam. Eye (Lond). 2018;32(2):375–83.

    CAS  Google Scholar 

  80. 80.

    Sharma A. Emerging simplified retinal imaging. Dev Ophthalmol. 2017;60:56–62.

    PubMed  Google Scholar 

  81. 81.

    Matimba A, et al. Tele-ophthalmology: opportunities for improving diabetes eye care in resource- and specialist-limited Sub-Saharan African countries. J Telemed Telecare. 2016;22(5):311–6.

    PubMed  Google Scholar 

  82. 82.

    Rajalakshmi R, et al. Automated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligence. Eye (Lond). 2018;32(6):1138–44.

    Google Scholar 

  83. 83.

    Pieczynski J, Grzybowski A. Review of diabetic retinopathy screening methods and programmes adopted in different parts of the world. Eur Ophthal Rev. 2015;9(1):49–55.

    Google Scholar 

  84. 84.

    Tozer K, Woodward MA, Newman-Casey PA. Telemedicine and diabetic retinopathy: review of published screening programs. J Endocrinol Diabetes. 2015;2(4):1–10.

    Google Scholar 

  85. 85.

    Li HK, et al. Telehealth practice recommendations for diabetic retinopathy, second edition. Telemed J E-Health. 2011;17(10):814–37.

    PubMed  Google Scholar 

  86. 86.

    Zimmer-Galler I, Zeimer R. Results of implementation of the DigiScope for diabetic retinopathy assessment in the primary care environment. Telemed J E Health. 2006;12(2):89–98.

    PubMed  Google Scholar 

  87. 87.

    Cuadros J, Bresnick G. EyePACS: an adaptable telemedicine system for diabetic retinopathy screening. J Diabetes Sci Technol. 2009;3(3):509–16.

    PubMed  PubMed Central  Google Scholar 

  88. 88.

    Massin P, et al. OPHDIAT: a telemedical network screening system for diabetic retinopathy in the Ile-de-France. Diabetes Metab. 2008;34(3):227–34.

    CAS  PubMed  Google Scholar 

  89. 89.

    Schulze-Dobold C, et al. Ophdiat((R)): five-year experience of a telemedical screening programme for diabetic retinopathy in Paris and the surrounding area. Diabetes Metab. 2012;38(5):450–7.

    CAS  PubMed  Google Scholar 

  90. 90.

    Abramoff MD, Suttorp-Schulten MS. Web-based screening for diabetic retinopathy in a primary care population: the EyeCheck project. Telemed J E Health. 2005;11(6):668–74.

    PubMed  Google Scholar 

  91. 91.

    Sampson CJ, et al. Stratifying the NHS Diabetic Eye Screening Programme: into the unknown? Diabet Med. 2016;33(12):1612–4.

    CAS  PubMed  Google Scholar 

  92. 92.

    Sanchez CR, et al. Ocular telemedicine for diabetic retinopathy and the Joslin Vision Network. Semin Ophthalmol. 2010;25(5–6):218–24.

    PubMed  Google Scholar 

  93. 93.

    Aiello LM, et al. Joslin Vision Network Validation Study: pilot image stabilization phase. J Am Optom Assoc. 1998;69(11):699–710.

    CAS  PubMed  Google Scholar 

  94. 94.

    Lim MC, et al. Diabetic retinopathy in diabetics referred to a tertiary centre from a nationwide screening programme. Ann Acad Med Singap. 2008;37(9):753–9.

    PubMed  Google Scholar 

  95. 95.

    Nathoo N, et al. The prevalence of diabetic retinopathy as identified by teleophthalmology in rural Alberta. Can J Ophthalmol. 2010;45(1):28–32.

    PubMed  Google Scholar 

  96. 96.

    Ng M, et al. Improving access to eye care: teleophthalmology in Alberta, Canada. J Diabetes Sci Technol. 2009;3(2):289–96.

    PubMed  PubMed Central  Google Scholar 

  97. 97.

    Ting DS, Tay-Kearney ML, Kanagasingam Y. Light and portable novel device for diabetic retinopathy screening. Clin Exp Ophthalmol. 2012;40(1):e40–6.

    PubMed  Google Scholar 

  98. 98.

    Zhang W, et al. Screening for diabetic retinopathy using a portable, noncontact, nonmydriatic handheld retinal camera. J Diabetes Sci Technol. 2017;11(1):128–34.

    PubMed  Google Scholar 

Download references



No funding or sponsorship was received for this study or publication of this article.


All named authors meet the international Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published.


B.J. Fenner, R.L.M. Wong, and G.S.W. Tan do not have any personal, financial, commercial, or academic conflicts of interest. W.C. Lam is a consultant for Novartis and Bayer. G.C.M. Cheung is a consultant for Topcon, Novartis, Bayer, Allergan, Roche, Boehringher-Ingelheim, and Samsung.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (, which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Author information



Corresponding author

Correspondence to Gemmy C. M. Cheung.

Additional information

Enhanced Digital Features

To view enhanced digital features for this article go to

Rights and permissions

This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fenner, B.J., Wong, R.L.M., Lam, WC. et al. Advances in Retinal Imaging and Applications in Diabetic Retinopathy Screening: A Review. Ophthalmol Ther 7, 333–346 (2018).

Download citation


  • Artificial intelligence
  • Deep learning
  • Diabetic retinopathy
  • Optical coherence tomography
  • Retina
  • Ultrawide field imaging